Hemab Therapeutics Holdings, Inc. (COAG) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Hemab Therapeutics Holdings, Inc. (COAG) closed at USD 29.94 on 2026-10-14, a change of -11.9 % over the past year, with a market capitalization of USD 1.52B.

Hemab Therapeutics Holdings, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Hemab Therapeutics Holdings, Inc. key figures

Previous close

USD 29.94 (2026-10-14)

1-year change

-11.9 %

Market cap

USD 1.52B

Enterprise value

USD 1.06B

P/E ratio (trailing)

-6.88

P/E ratio (forward)

-12.77

EPS (trailing)

-4.73

EPS (forward)

-2.55

PEG ratio

n/a

Price to book

3.34

Revenue growth

n/a

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

5.66

Employees

59

Analyst consensus (third-party)

none

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Hemab Therapeutics Holdings, Inc.

Hemab Therapeutics Holdings, Inc. operates as a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience in United States of America and Denmark. Its products includes (HMB-001), is a bispecific antibody currently in Phase 1/2 clinical development for the prophylactic treatment of Glanzmann thrombasthenia and Phase 2 clinical development for the prophylactic treatment of Factor VII deficiency; and second clinical-stage asset, HMB-002, is a monovalent antibody in Phase 1/2 clinical development for the subcutaneous prophylactic treatment of Von Willebrand disease. It also advances multiple preclinical and discovery-stage assets. The company was founded in 2020 and is based in Cambridge, Massachusetts.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Hemab Therapeutics Holdings, Inc. and compare it with other stocks.